Search

Your search keyword '"E. Megalakaki"' showing total 5 results
Start Over Author "E. Megalakaki" Database OpenAIRE
5 results on '"E. Megalakaki"'

1. RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES

Author

A. Koumarianou, Argyris Symeonidis, Leylagül Kaynar, Saime Paydas, Nikolaos Kanellias, Chezi Ganzel, G. Isenberg, Themistoklis Karmiris, Olga Meltem Akay, E. Megalakaki, M. Ozgur, George Karianakis, Eleftheria Hatzimichael, Miri Zektser, M. Palassopoulou, Eirini Katodritou, O. Gutwein, Chrysovalantou Chatzidimitriou, Stamatios Karakatsanis, Maria Tsirogianni, Tulin Firatli Tuglular, Maria K. Angelopoulou, Z. Mellios, Anat Gafter-Gvili, Effimia Vrakidou, T.P. Vassilakopoulos, Gabriella Gainaru, Christina Kalpadakis, A. C. Atalar, Ronit Gurion, Marina P. Siakantaris, Panayiotis Tsirigotis, Panagiotis Zikos, Sotirios G. Papageorgiou, Burhan Ferhanoglu, Theoni Leonidopoulou, Tamar Tadmor, Netanel A. Horowitz, and A. Piperidou

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, medicine, Rituximab, Primary Mediastinal Large B-Cell Lymphoma, Hematology, General Medicine, EPOCH (chemotherapy), Radiology, business, medicine.drug
Published
2021

2. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group

Author

Papageorgiou, S.G. Vasilatou, D. Kontos, C.K. Kotsianidis, I. Symeonidis, A. Galanopoulos, A.G. Hatzimichael, E. Megalakaki, A. Poulakidas, E. Diamantopoulos, P. Vassilakopoulos, T.P. Zikos, P. Papadaki, H. Mparmparousi, D. Bouronikou, E. Panayiotidis, P. Viniou, N.-A. Pappa, V.

Abstract

In this study, we investigated the incidence and prognostic impact of monosomal karyotype (MK) in 405 higher-risk Myelodysplastic Syndromes (MDS) patients treated with 5-AZA. The MK was present in 66 out of 405 (16.3%) patients, most of whom had complex karyotype (CK). MK was strongly associated with CK and the cytogenetic risk defined according to IPSS-R, as well as with high-risk disease, according to IPSS (P =.029), IPSS-R (P

Published
2018

4. Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival (Annals of Hematology, (2018), 97, 9, (1671-1682), 10.1007/s00277-018-3361-2)

Author

Katodritou, E. Kyrtsonis, M.-C. Delimpasi, S. Kyriakou, D. Symeonidis, A. Spanoudakis, E. Vasilopoulos, G. Anagnostopoulos, A. Kioumi, A. Zikos, P. Aktypi, A. Briasoulis, E. Megalakaki, A. Repousis, P. Adamopoulos, I. Gogos, D. Kotsopoulou, M. Pappa, V. Papadaki, E. Fotiou, D. Nikolaou, E. Giannopoulou, E. Hatzimichael, E. Giannakoulas, N. Douka, V. Kokoviadou, K. Timotheatou, D. Terpos, E.

Abstract

The original version of this article contained a mistake. The name of Eirini Katroditou should have been Eirini Katodritou. The original article has been corrected. © 2018, The Author(s).

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results